fluticasone propionate · Teva Pharm · NDA 208798
Armonair Respiclick
Earliest generic entry, as listed · earliest of 4 marketed strengths
20 Feb 2040
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 11969544.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11969544 | — | 20 Feb 2040 |
| US 11969544 | product | 20 Aug 2039 |
| US 10195375 | — | 14 Aug 2031 |
| US 10195375 | product | 14 Feb 2031 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 208798 · 001 · RLD · discontinued | powder, inhalation | 0.055MG/INH | 20 Feb 2040 |
| 208798 · 002 · RLD · discontinued | powder, inhalation | 0.113MG/INH | 20 Feb 2040 |
| 208798 · 003 · RLD · discontinued | powder, inhalation | 0.232MG/INH | 20 Feb 2040 |
| 208798 · 007 · RLD · discontinued | powder, inhalation | 0.03MG/INH | 20 Feb 2040 |